Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma (LYEL)
NASDAQ:LYEL
Holding LYEL?
Track your performance easily
LYEL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.58 - $3.26
Previous Close$0.61
Volume2.81M
Average Volume (3M)1.45M
Market Cap
$179.01M
Enterprise Value-$210.10M
Total Cash (Recent Filing)$440.55M
Total Debt (Recent Filing)$51.44M
Price to Earnings (P/E)―
Beta2.67
Next Earnings
Feb 26, 2025EPS Estimate
-$0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding279,220,614
10 Day Avg. Volume1,828,413
30 Day Avg. Volume1,447,967
Standard Deviation0.25
R-Squared0.00823
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.32
Price to Sales (P/S)2715.53
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.33K
Enterprise Value/Gross Profit-1.62K
Enterprise Value/Ebitda1.18
Forecast
1Y Price Target
$1.00Price Target Upside63.21% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is LYEL a Buy, Before Earnings?
PremiumCompany Announcements
Lyell Immunopharma’s Strategic Moves and Leadership Expansion
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial Phase 1/2 data of IMPT-314 in 2L+ LBCL to be presented at ASH, with promising results from a single-center Phase 1 study showing 92% ORR and 77% CRs.
Financial PositionLyell concluded Q3 with $461M in cash, ensuring a strong operational runway expected to last into 2027.
Strategic AcquisitionsThe acquisition of ImmPACT Biosciences directs Lyell Immunopharma's focus on an innovative CAR-T cell therapy targeting B-cell lymphomas.
Bears Say
Acquisition ChallengesThe acquisition of ImmPACT Bio for its CD19/ CD20 CAR-T IMPT-314 raises eyebrows and complicates the story.
Market CompetitionThe CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.
Pipeline DevelopmentDevelopment of several legacy pipeline programs, including LYL797 and LYL845, has been discontinued with no sufficient evidence of benefits from the second-generation ROR1 CAR-T.
---
Ownership Overview
17.61% Insiders
7.88% Mutual Funds
24.52% Other Institutional Investors
43.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $0.58 and its highest was $3.25 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Currently, no data Available
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Feb 26, 2025 which is in 66 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Nov 07, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -$0.19.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 292,161,650 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Among the largest hedge funds holding Lyell Immunopharma’s share is EntryPoint Capital, LLC. It holds Lyell Immunopharma’s shares valued at 287K.
---
Lyell Immunopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.00 (63.21% Upside)
$1.00 (63.21% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 187.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.6%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.09%
12-Months-Change
Fundamentals
Return on Equity
-33.22%
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
---
LYEL Stock 12 Month Forecast
Average Price Target
$1.00
▲(63.21% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-66.20%
reiterated a buy rating 7 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -66.20% per trade.
---